Dialysis Player Fresenius Medical’s Q4 Sales Hold Steady: Details

by

in

Tuesday, Fresenius Medical Care AG (NYSE:FMS) reported fourth-quarter 2023 revenue of €4.9 billion ($5.37 billion, almost in line with the consensus of $5.35 billion) (+7% at constant currency, +3% organic), which remained flat Y/Y

Care Delivery revenue remained flat at €3.9 billion (+8% at constant currency, +2% organic). Care Enablement revenue declined slightly by 1% to €1.4 billion (+5% at constant currency, +6% organic). 

Higher product sales and higher average prices partly offset the negative exchange rate effects.

Adjusted EPS increased 4% to €0.88 (+8% at constant currency). Adjusted EPADS reached $0.47, beating the consensus of $0.32.

As of December 31, 2023, Fresenius Medical Care …

Full story available on Benzinga.com


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *